Author Archives | BeckyShadle
BeckyShadle - who has written 34 posts on FavStocks.
A business savvy Seattle native who has run a successful Seattle based business for 9 years. Becky likes to keep a close watch on the Biotechnolgy sector and maintains long term hold positions (20% portfolio) and enjoys the high risks and the lucrative returns.
She likes to keep watch on companies in all stages of FDA drug approval. Combining key information with an unemotional view she hopes that you might be able to spot some big opportunities in the biotech sector.
Enzon drug Gets FDA Approval (NASDAQ:ENZN)
On a Monday afternoon, Enzon Pharmaceuticals made an announcement that FDA Oncologic Drug Advisory Committee has voted in the favor of and has approved the use of Pegintron as a treatment in addition to surgery in patients with metastatic melanoma. The news of FDA approval has boosted Enzon Pharmaceuticals and even the shares of the [...]
Continue reading...Trimeris New Agreement (NASDAQ:TRMS)
5 October 2009
Comments Off
Trimeris Inc today has announced that they have entered into a definitive merger agreement with the Korean corporation, Arigene Co. Ltd., which is currently trading on the Korean Securities Dealer Association Quotation System. Trimeris Inc is a biopharmaceutical company that is currently engaged in the commercialization of therapeutic agents of viral diseases. They are well [...]
Continue reading...Caraco reaches agreement with FDA panel (AMEX: CPD)
2 October 2009
Comments Off
Caraco Pharmaceuticals, an US-based subsidiary of Sun Pharma has agreed to go through a series of actions as per the requirements of the Food and Drug Administration of the United States of America after which the FDA would lift their ban on certain manufacturing units of Caraco Pharmaceuticals. The voluntary agreement was reached between the [...]
Continue reading...ImmunoCellular Therapeutics Delivers on Key Milestones (OTC:IMUC)
1 October 2009
Comments Off
ImmunoCellular just announced their lead monoclonal antibody product candidates ICT-109 had positive result in their lead study of detecting cancerous tissues. The results were statically significant suggesting that this antibody can determine if tissues are cancerous or non-cancerous in plasma and serum study sets. These results from the study lead IMUC to believe that this ICT-109 molecule can play an important [...]
Continue reading...
6 October 2009
Comments Off